My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Biogen Idec (NQ:BIIB)

192.03 -0.05 (-0.03%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

48 49 Next >

Biogen Earnings Flat; Biotech Giant Raises Guidance ↗

August 01, 2024

Sales slightly topped. Shares edged higher early Thursday.

Via Investor's Business Daily

The Analyst Verdict: Biogen In The Eyes Of 12 Experts ↗

July 29, 2024

Via Benzinga

Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗

July 29, 2024

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.

Via Benzinga

Topics Economy

Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy? ↗

July 29, 2024

Biogen stock has slipped 18% so far this year.

Via The Motley Fool

Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events ↗

July 26, 2024

The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards...

Via Benzinga

Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug ↗

July 26, 2024

Biogen partner Eisai is planning to ask European regulators to re-examine their decision.

Via Investor's Business Daily

Key Takeaways From Biogen Analyst Ratings ↗

July 12, 2024

Via Benzinga

Will BIOGEN INC breakout? ↗

July 11, 2024

Technical Insights for BIOGEN INC (NASDAQ:BIIB): Is a Breakout Imminent?

Via Chartmill

Forecasting The Future: 19 Analyst Projections For Biogen ↗

June 26, 2024

Via Benzinga

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 26, 2024

Via Benzinga

Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints ↗

July 24, 2024

Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps.

Via Benzinga

(BIIB) - Analyzing Biogen's Short Interest ↗

June 07, 2024

Via Benzinga

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails ↗

July 24, 2024

The companies are no longer developing their drug for essential tremor treatment.

Via Investor's Business Daily

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst ↗

July 22, 2024

Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...

Via Benzinga

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong ↗

July 22, 2024

Biogen previously decided against opting into Ionis' Angelman program.

Via Investor's Business Daily

Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense ↗

July 16, 2024

Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.

Via Investor's Business Daily

Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings' ↗

July 15, 2024

Via Benzinga

Topics Bankruptcy

Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split ↗

July 15, 2024

Revenue is climbing at these two drug companies -- and the trend should continue.

Via The Motley Fool

Did Eli Lilly Just Get a Leg Up on Novo Nordisk? ↗

July 13, 2024

Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.

Via The Motley Fool

3 Highly Rated Biotech Stocks for Your July Buy List ↗

July 05, 2024

Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.

Via InvestorPlace

Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst ↗

July 03, 2024

The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce...

Via Benzinga

Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai ↗

July 02, 2024

The company is on deck to rival Biogen and Eisai's Leqembi.

Via Investor's Business Daily

This Is Massive News for Eli Lilly Investors ↗

June 29, 2024

A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.

Via The Motley Fool

The 3 Best Healthcare Stocks to Buy in June 2024 ↗

June 15, 2024

Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on.

Via InvestorPlace

4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024 ↗

June 12, 2024

Consider making moves in these securities, each of which has news that is impacting their share price either positively or negatively.

Via InvestorPlace

Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst ↗

June 11, 2024

Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi.

Via Benzinga

Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win ↗

June 11, 2024

An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday.

Via Investor's Business Daily

Why Is Eli Lilly Stock Trading Higher Premarket Tuesday? ↗

June 11, 2024

Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting...

Via Benzinga

Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug ↗

June 10, 2024

The FDA isn't bound by the committee's recommendation, but often follows it.

Via Investor's Business Daily

The 3 Most Undervalued Pharma Stocks to Buy in June 2024 ↗

June 06, 2024

These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines.

Via InvestorPlace

Topics Economy

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

48 49 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.